OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this compassionate use study, for two patients with thrombotic microangiopathy, is to provide expanded access to patients who have participated in the clinical trial OMS721-TMA-001 and in whom improvement in their disease markers was observed while on treatment or to patients who could otherwise benefit from the treatment. This is a treatment protocol; not a research protocol.Therefore, only patients in study OMS721-TMA-001 deemed eligible by the investigator may participate.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of Interventions for Hospital Medical Thromboprophylaxis: a Bicentric Swiss Quality-improvement Study

NCT05306821

Venous Thromboembolism

UNKNOWN NA

Michelangelo - Oasis 5

NCT00139815

Thromboembolism

COMPLETED PHASE3

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

NCT00311753

Embolism

COMPLETED PHASE3

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713

Community-acquired Pneumonia

RECRUITING PHASE3

Delivery and Implementation of a Randomised Crossover Trial on Thrombosis

NCT06937372

Hip Fractures Venous Thromboembolism (VTE)

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is open-label, expanded access study to provide continued OMS721 treatment for compassionate use to patients who have participated in clinical trial OMS721-TMA-001. Patients will be eligible if markers of disease activity, such as platelet count, LDH, and haptoglobin, were observed to improve during the study or if the patients disease activity remained stable, but they could be treated with a higher dose that may be beneficial. Safety measures of adverse events and laboratory measures will be monitored. Markers of disease activity, pharmacokinetics and ex vivo pharmacodynamics will also be monitored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombotic Microangiopathy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

OMS721

Human IgG4 MASP-2 Monoclonal Antibody

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have a diagnosis of thrombotic microangiopathy related to aHUS, TTP or stem cell transplant.
* Have completed treatment in clinical trial OMS721-TMA-001.
* Investigator determined that continued treatment with OMS721 could be beneficial.
* Aged 18 years or older.